Promoted Content
Promoted Content

Find Oncology Drugs in Phase II Clinical Development in SPAIN

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BO-112,Pembrolizumab

            Therapeutic Area: Oncology Product Name: BO-112

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Pivotal

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 21, 2020

            Details:

            First cohort of patients has been recruited in a Phase IIa study to assess Highlight’s lead program BO-112 in combination with an anti-PD1 therapy, in patients with liver metastasis from colorectal or gastric/gastro-esophageal junction cancers.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Iadademstat,Azacitidine

            Therapeutic Area: Oncology Product Name: ORY-1001

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 15, 2020

            Details:

            The article describes the firstin- human clinical trial in acute myeloid leukemia (AML) patients with iadademstat (ORY-1001), the most potent and selective KDM1A inhibitor to date. Data support safety of the drug in elderly patients with acute leukemia .

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Iadademstat,Carboplatin,Etoposide

            Therapeutic Area: Oncology Product Name: ORY-1001

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 17, 2020

            Details:

            The combination of the three agents, iadademstat and carboplatin-etoposide, produced encouraging signs of clinical efficacy, with an objective response rate (ORR) of 40% (4 partial remissions in 10 patients) and a mean duration of response of 4.5 months.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BO-112,Pembrolizumab

            Therapeutic Area: Oncology Product Name: BO-112

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 26, 2020

            Details:

            Highlight Therapeutics dosed first patient in a Phase IIa clinical evaluation of the combination of BO-112, Highlight's lead program, and KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy, in patients with select advanced stage solid tumors with liver metastases.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Iadademstat,Azacitidine

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 02, 2020

            Details:

            ALICE is a single arm, open-label Phase IIa clinical trial to evaluate the safety, tolerability, dose finding and efficacy of iadademstat in combination with azacitidine in older patients with AML in first line therapy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lurbinectedin

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 17, 2020

            Details:

            PharmaMar submitted the NDA to FDA in December 2019 based on data from the Phase II monotherapy basket trial, which included evaluation of lurbinectedin for the treatment of relapsed SCLC.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lurbinectedin,Atezolizumab

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 14, 2020

            Details:

            PharmaMar to start a Phase I-II study to determine the recommended dose and efficacy of lurbinectedin in combination with atezolizumab in patients with advanced Small Cell Lung Cancer (SCLC).